UNDAUNTED

so Michele, who is living with PNH, can spend more time riding her beloved horse

Male Apellis employee holding a horse saddle

Luis
Supply Chain at Apellis

We are a global biopharmaceutical company leveraging courageous science, creativity, and compassion to deliver life-changing medicines. Leaders in targeted C3 therapies, we aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases including those within hematology, ophthalmology, nephrology, and neurology.

Learn More
Folded page of a newspaper

Latest news

October 27, 2020

Apellis and Sobi Enter Collaboration for Global Co-development and Ex-US Commercialization of Systemic Pegcetacoplan in Rare Diseases with Urgent Need for New Treatments

October 19, 2020

Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA)

October 15, 2020

Apellis Announces New Data Demonstrating Correlation between Complement Activation and COVID-19 Severity

Newsroom
A man with a baby in a baby carrier

At the heart of our company is the belief that exceptional science and compassion are not mutually exclusive.

FOR PATIENTS
Erlenmeyer flask, which represents the pre-clinical and clinical studies sponsored by Apellis Pharmaceuticals

We are advancing therapies

for PNH, geographic atrophy, ALS, C3G / IC-MPGN, and CAD.

PIPELINE
3 arrows of different lengths, which represents the development status of pre-clinical and clinical studies for C3 complement targeted therapies

Our lead investigational products

are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.

CLINICAL TRIALS

we replace impossible with How

so that Alexander, who is living with C3 glomerulopathy, can take his pug for a hike

We challenge conventional thinking and always question if there's a better way.

Join Us
Female Apellis employee holding a pug

Patricia
Quality Assurance at Apellis